Monday, July 18, 2016
July 18, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. completed a Series A round of financing from Arkin Bio Ventures and from senior biopharmaceutical executives. The current financing will allow Censa to aggressively accelerate product development towards regulatory approval in target orphan diseases.
About Censa Pharmaceuticals:
Censa Pharmaceuticals Inc. is a Boston based biotechnology company developing medicines to improve the lives of patients with debilitating diseases. Censa lead product CNSA-001 targets orphan metabolic and central nervous system diseases.
About Arkin Bio Ventures
Arkin Bio Ventures identifies, invests in, and accompanies innovative early and mid-stage companies with game-changing breakthroughs in areas such as: immunotherapy, cancer, metabolism, microbiome, CNS, autoimmune diseases, orphan diseases and drug delivery platforms.
Head Corporate Development